 Lindsey Dayer
Concepts (106)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 13 | 2025 | 562 | 3.270 |
Why?
| | Palliative Care | 5 | 2024 | 188 | 1.890 |
Why?
| | Chronic Pain | 5 | 2024 | 175 | 1.620 |
Why?
| | Medication Adherence | 4 | 2016 | 129 | 1.370 |
Why?
| | Students, Pharmacy | 4 | 2024 | 123 | 1.210 |
Why?
| | Pharmacists | 2 | 2019 | 143 | 1.060 |
Why?
| | Inappropriate Prescribing | 1 | 2025 | 21 | 0.950 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2024 | 9 | 0.940 |
Why?
| | Pain, Postoperative | 2 | 2025 | 160 | 0.930 |
Why?
| | Drug Overdose | 3 | 2023 | 159 | 0.900 |
Why?
| | Computers, Handheld | 2 | 2013 | 25 | 0.860 |
Why?
| | Accidental Falls | 1 | 2024 | 102 | 0.830 |
Why?
| | Tramadol | 4 | 2024 | 30 | 0.820 |
Why?
| | Hydroxyurea | 1 | 2022 | 29 | 0.820 |
Why?
| | Anxiety | 1 | 2024 | 276 | 0.810 |
Why?
| | Patient Discharge | 1 | 2025 | 322 | 0.800 |
Why?
| | Health Personnel | 3 | 2016 | 250 | 0.800 |
Why?
| | Anemia, Sickle Cell | 1 | 2022 | 94 | 0.770 |
Why?
| | Opioid-Related Disorders | 3 | 2023 | 387 | 0.760 |
Why?
| | Education, Pharmacy | 4 | 2024 | 144 | 0.710 |
Why?
| | Guidelines as Topic | 1 | 2019 | 110 | 0.640 |
Why?
| | Neuralgia | 3 | 2023 | 63 | 0.560 |
Why?
| | Humans | 28 | 2025 | 50201 | 0.520 |
Why?
| | Retrospective Studies | 13 | 2025 | 6190 | 0.520 |
Why?
| | Case-Control Studies | 4 | 2025 | 1145 | 0.460 |
Why?
| | Health Literacy | 1 | 2016 | 129 | 0.450 |
Why?
| | Sulfonamides | 1 | 2014 | 125 | 0.420 |
Why?
| | Clinical Competence | 1 | 2016 | 397 | 0.420 |
Why?
| | Adult | 10 | 2025 | 13486 | 0.410 |
Why?
| | Pyrimidines | 1 | 2014 | 192 | 0.410 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 489 | 0.390 |
Why?
| | Aged | 7 | 2025 | 9505 | 0.380 |
Why?
| | Melanoma | 1 | 2014 | 281 | 0.360 |
Why?
| | Pain Management | 2 | 2024 | 167 | 0.360 |
Why?
| | Female | 11 | 2025 | 26829 | 0.350 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 1580 | 0.340 |
Why?
| | Self Report | 2 | 2024 | 202 | 0.330 |
Why?
| | Breast Neoplasms | 3 | 2023 | 1187 | 0.330 |
Why?
| | Male | 8 | 2025 | 25572 | 0.330 |
Why?
| | Analgesics | 3 | 2024 | 103 | 0.310 |
Why?
| | Aged, 80 and over | 3 | 2024 | 3158 | 0.310 |
Why?
| | United States | 6 | 2023 | 4898 | 0.310 |
Why?
| | Middle Aged | 6 | 2025 | 12356 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1000 | 0.300 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1176 | 0.290 |
Why?
| | Pharmaceutical Services | 2 | 2018 | 52 | 0.270 |
Why?
| | Curriculum | 3 | 2024 | 397 | 0.270 |
Why?
| | Outpatients | 2 | 2024 | 115 | 0.260 |
Why?
| | Risk Factors | 2 | 2025 | 3644 | 0.260 |
Why?
| | Preceptorship | 1 | 2024 | 19 | 0.240 |
Why?
| | Pharmacy | 2 | 2023 | 54 | 0.230 |
Why?
| | Problem-Based Learning | 1 | 2024 | 47 | 0.230 |
Why?
| | Pain | 2 | 2022 | 373 | 0.210 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 382 | 0.210 |
Why?
| | Ambulatory Care | 1 | 2024 | 225 | 0.210 |
Why?
| | Longitudinal Studies | 1 | 2024 | 700 | 0.200 |
Why?
| | Sex Factors | 1 | 2024 | 700 | 0.200 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 115 | 0.190 |
Why?
| | Prevalence | 1 | 2024 | 960 | 0.190 |
Why?
| | Age Factors | 1 | 2024 | 1096 | 0.180 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2021 | 79 | 0.180 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2020 | 18 | 0.180 |
Why?
| | Acetaminophen | 1 | 2022 | 274 | 0.170 |
Why?
| | Cohort Studies | 2 | 2022 | 1414 | 0.160 |
Why?
| | Hydrocodone | 3 | 2024 | 20 | 0.160 |
Why?
| | Oxycodone | 3 | 2024 | 26 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 121 | 0.160 |
Why?
| | Epidemics | 1 | 2018 | 19 | 0.160 |
Why?
| | History, 21st Century | 1 | 2018 | 56 | 0.160 |
Why?
| | Critical Illness | 1 | 2021 | 301 | 0.160 |
Why?
| | College Admission Test | 1 | 2018 | 13 | 0.160 |
Why?
| | History, 20th Century | 1 | 2018 | 95 | 0.160 |
Why?
| | School Admission Criteria | 1 | 2018 | 35 | 0.150 |
Why?
| | Schools, Pharmacy | 1 | 2018 | 52 | 0.150 |
Why?
| | Patient Care Team | 1 | 2019 | 258 | 0.150 |
Why?
| | Cannabis | 1 | 2019 | 141 | 0.140 |
Why?
| | Young Adult | 2 | 2024 | 4052 | 0.140 |
Why?
| | Medicare | 3 | 2023 | 245 | 0.140 |
Why?
| | Educational Measurement | 1 | 2018 | 204 | 0.140 |
Why?
| | Reminder Systems | 1 | 2016 | 27 | 0.130 |
Why?
| | Herb-Drug Interactions | 1 | 2016 | 31 | 0.130 |
Why?
| | Medication Therapy Management | 1 | 2016 | 24 | 0.130 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 482 | 0.130 |
Why?
| | Drug Interactions | 1 | 2016 | 208 | 0.130 |
Why?
| | Administration, Oral | 1 | 2016 | 432 | 0.120 |
Why?
| | Community Pharmacy Services | 1 | 2016 | 67 | 0.120 |
Why?
| | Carboplatin | 1 | 2014 | 51 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 44 | 0.110 |
Why?
| | Quality of Life | 1 | 2019 | 843 | 0.110 |
Why?
| | Neoplasms | 1 | 2019 | 1233 | 0.080 |
Why?
| | Ibuprofen | 1 | 2022 | 20 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 93 | 0.050 |
Why?
| | Thyroid Gland | 1 | 2022 | 73 | 0.050 |
Why?
| | Naloxone | 1 | 2023 | 79 | 0.050 |
Why?
| | Propensity Score | 1 | 2022 | 126 | 0.050 |
Why?
| | Narcotic Antagonists | 1 | 2023 | 135 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2023 | 133 | 0.050 |
Why?
| | Health Care Costs | 1 | 2022 | 168 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 213 | 0.050 |
Why?
| | Amines | 1 | 2020 | 39 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 703 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 224 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2188 | 0.040 |
Why?
| | Universities | 1 | 2018 | 169 | 0.040 |
Why?
| | Prospective Studies | 1 | 2022 | 2396 | 0.030 |
Why?
| | Arkansas | 1 | 2022 | 1988 | 0.030 |
Why?
|
|
Dayer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|